Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity
2018年6月13日 更新者:Seong-Gyu Ko、Kyunghee University Medical Center
A Double Blind, Randomized, Multicenter, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Euiiyin-tang on Obese Patients
The hypothesis of this study is obese patient with Euiiyin-tang for 12 weeks will show a superior reduction compared to those taking the placebo.
研究概览
详细说明
This study has two arms, Euiiyin-tang and placebo group.
Inclusion of 80 patient each arm.
They will be screened at first visit.
At the baseline, that is the second visit, they will be evaluated each outcomes including weight, waist circumference, lipid profile (total cholesterol, triglyceride), CRP (C-reactive protein), visceral fat area and subcutaneous fat area using abdominal computed tomography (CT), questionnaires of QoL (Quality of Life) and eating attitudes, etc.
The Euiiyin-tang will provide to the patients from the baseline, it contains 4 weeks of serving.
After 4 weeks, the visit 3, the evaluation procedure will be repeated except lipid profile, CRP, abdominal CT.
Another Euiiyin-tang of 4 weeks will be given to the patient.
The visit 4, 4 weeks after the visit 3, the same procedure will be repeated.
The visit 5, 12 weeks after from the baseline, the patient will be evaluated including weight, waist circumference, lipid profile, CRP, visceral fat area and subcutaneous fat area using abdominal computed tomography, questionnaires of QoL and eating attitudes, etc.
研究类型
介入性
注册 (实际的)
149
阶段
- 阶段2
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Incheon、大韩民国、405-760
- Gachon University Gil Medical Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
女性
描述
Inclusion Criteria:
- Women aged 18-65 years old
- Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI 27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled (SBP ≤ 145mmHg, DBP ≤ 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose < 7.8mmol/L(140mg/dL) 2.4. BMI 27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening
- Agreed to low-calorie diet during the trial
- Written informed consent of the trial
Exclusion Criteria:
- Endocrine disease such as hypothyroidism, Cushing's syndrome, etc.
- Heart disease (heart failure, angina pectoris, myocardial infarction)
- Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)
- Malignant tumour or lung disease
- Cholelithiasis
- Severe renal disability (SCr > 2.0 mg/dL)
- Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
- Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL) or over
- Narrow angle glaucoma
- History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)
- History of stroke or temporary ischemic cardioplegia
- History or existence of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
- Use of medication that could have effect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having effect on absorption, metabolism, excretion)
- Use of β--blocker or diuretic as hypertension medication within last 3 months
- Use of medication for central nervous system or central active weight reduction medication
- Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
- Difficult to measure anthropometric dimensions because of anatomical change such as resection
- Surgical history for weight reduction; bariatric surgery, etc.
- Unable to follow instructions of the trial as judged by investigator
- Women who were pregnant, lactating, planning a pregnancy or women of childbearing age who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) (Women of childbearing age indicate within 2 years of menopause who did not receive hysterectomy, bilateral tubal ligation, bilateral oophorectomy, etc.)
- Use of other investigational product within last 1 month
- Reduction over 10% of the previous weight within 6 months
- Decided to stop smoking within last 3 months; however, keeping irregular smoking habit
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Euiiyin-tang
powder type, 3 times per day before the meal, 12 weeks total
|
Korean medicinal herbal drug
|
安慰剂比较:Placebo
powder type, 3 times per day before the meal, 12 weeks total
|
Placebo drug, same odor and formula as Euiiyin-tang
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Weight reduction
大体时间:between baseline and 12 weeks
|
between baseline and 12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
C-reactive protein (CRP)
大体时间:baseline and 12 weeks
|
baseline and 12 weeks
|
|
Blood pressure
大体时间:baseline, 4 weeks, 8 weeks, and 12 weeks
|
baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Blood glucose
大体时间:baseline and 12 weeks
|
baseline and 12 weeks
|
|
Waist/hip ratio
大体时间:4 weeks, 8 weeks, and 12 weeks
|
4 weeks, 8 weeks, and 12 weeks
|
|
Waist circumference
大体时间:baseline, 4 weeks, 8 weeks, and 12 weeks
|
baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Korean Obesity-related Quality of Life scale
大体时间:baseline and 12 weeks
|
baseline and 12 weeks
|
|
Korean version of Eating Attitudes Test-26
大体时间:baseline and 12 weeks
|
baseline and 12 weeks
|
|
Total cholesterol
大体时间:baseline and 12 weeks
|
baseline and 12 weeks
|
|
Triglyceride
大体时间:baseline and 12 weeks
|
baseline and 12 weeks
|
|
Visceral fat area
大体时间:baseline and 12 weeks
|
Using abdominal computed tomography
|
baseline and 12 weeks
|
Subcutaneous fat area
大体时间:baseline and 12 weeks
|
Using abdominal computed tomography
|
baseline and 12 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Yoon-kyung SONG, KMD、Gachon University Medical Center
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Cheon C, Song YK, Ko SG. Efficacy and safety of Euiiyin-tang in Korean women with obesity: A randomized, double-blind, placebo-controlled, multicenter trial. Complement Ther Med. 2020 Jun;51:102423. doi: 10.1016/j.ctim.2020.102423. Epub 2020 May 21.
- Cheon C, Jang S, Park JS, Ko Y, Kim DS, Lee BH, Song HJ, Song YK, Jang BH, Shin YC, Ko SG. Euiiyin-tang in the treatment of obesity: study protocol for a randomised controlled trial. Trials. 2017 Jun 21;18(1):289. doi: 10.1186/s13063-017-2039-8.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年4月1日
初级完成 (实际的)
2015年2月1日
研究完成 (实际的)
2017年6月1日
研究注册日期
首次提交
2012年11月2日
首先提交符合 QC 标准的
2012年11月8日
首次发布 (估计)
2012年11月9日
研究记录更新
最后更新发布 (实际的)
2018年6月15日
上次提交的符合 QC 标准的更新
2018年6月13日
最后验证
2018年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Euiiyin-tang的临床试验
-
Gachon University Gil Oriental Medical HospitalKyung Hee University Hospital at Gangdong; DongGuk University; Kyunghee University Medical Center 和其他合作者完全的
-
University of Medicine and Pharmacy at Ho Chi Minh...完全的
-
University of Medicine and Pharmacy at Ho Chi Minh...完全的
-
Kil Yeon LeeNational Research Foundation of Korea招聘中